AU2017289315B2 - Heteroaromatic derivatives as NIK inhibitors - Google Patents
Heteroaromatic derivatives as NIK inhibitors Download PDFInfo
- Publication number
- AU2017289315B2 AU2017289315B2 AU2017289315A AU2017289315A AU2017289315B2 AU 2017289315 B2 AU2017289315 B2 AU 2017289315B2 AU 2017289315 A AU2017289315 A AU 2017289315A AU 2017289315 A AU2017289315 A AU 2017289315A AU 2017289315 B2 AU2017289315 B2 AU 2017289315B2
- Authority
- AU
- Australia
- Prior art keywords
- substituted
- 4alkyl
- optionally
- atoms
- group
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16177104 | 2016-06-30 | ||
| EP16177104.3 | 2016-06-30 | ||
| PCT/EP2017/066120 WO2018002217A1 (en) | 2016-06-30 | 2017-06-29 | Heteroaromatic derivatives as nik inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU2017289315A1 AU2017289315A1 (en) | 2019-01-24 |
| AU2017289315B2 true AU2017289315B2 (en) | 2021-04-01 |
Family
ID=56296645
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017289315A Ceased AU2017289315B2 (en) | 2016-06-30 | 2017-06-29 | Heteroaromatic derivatives as NIK inhibitors |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11136311B2 (enExample) |
| EP (1) | EP3478675B1 (enExample) |
| JP (1) | JP6936815B2 (enExample) |
| KR (1) | KR102517352B1 (enExample) |
| CN (1) | CN109641882B (enExample) |
| AU (1) | AU2017289315B2 (enExample) |
| CA (1) | CA3027416A1 (enExample) |
| ES (1) | ES2805976T3 (enExample) |
| WO (1) | WO2018002217A1 (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11001569B2 (en) | 2016-01-22 | 2021-05-11 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors |
| WO2017125530A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New substituted cyanoindoline derivatives as nik inhibitors |
| CN109641882B (zh) | 2016-06-30 | 2022-10-28 | 杨森制药有限公司 | 作为nik抑制剂的杂芳族衍生物 |
| ES2837157T3 (es) | 2016-06-30 | 2021-06-29 | Janssen Pharmaceutica Nv | Derivados de cianoindolina como inhibidores de NIK |
| KR102797697B1 (ko) | 2018-05-25 | 2025-04-22 | 에이2에이 파마수티칼스, 잉크. | 신종 항암제 후보로서, 매우 강력한 tacc3 억제제 |
| AU2019203034B1 (en) * | 2018-07-25 | 2019-09-26 | Hanmi Pharm. Co., Ltd. | Pyrimidine compounds and pharmaceutical compositions for preventing or treating cancers including the same |
| KR101954370B1 (ko) | 2018-07-25 | 2019-03-05 | 한미약품 주식회사 | 피리미딘 화합물 및 이를 포함하는 암의 예방 또는 치료용 약학 조성물 |
| PH12021551985A1 (en) | 2019-02-22 | 2022-08-22 | Hanmi Pharmaceutical Co Ltd | Pharmaceutical composition comprising flt3 inhibitor and hypomethylating agent for treating acute myeloid leukemia |
| LT3976597T (lt) | 2019-05-31 | 2024-10-10 | Janssen Pharmaceutica Nv | Nf-κb indukuojančios kinazės mažos molekulės inhibitoriai |
| KR102816656B1 (ko) | 2019-06-25 | 2025-06-02 | 인벤티스바이오 컴퍼니 리미티드 | 헤테로고리 화합물, 이의 제조방법 및 이의 사용방법 |
| KR20210002015A (ko) | 2019-06-27 | 2021-01-06 | 한미약품 주식회사 | Flt3 저해제 및 화학치료제를 포함하는 급성 골수성 백혈병 치료용 약학적 조성물 |
| EP4323351A4 (en) * | 2021-04-12 | 2025-07-30 | A2A Pharmaceuticals Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER |
| JP2025509965A (ja) | 2022-03-24 | 2025-04-11 | エーツーエー ファーマシューティカルズ インコーポレーテッド | がんを治療するための組成物及び方法 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002079197A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| WO2009158011A1 (en) * | 2008-06-26 | 2009-12-30 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| WO2010042337A1 (en) * | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE396978T1 (de) | 1999-10-07 | 2008-06-15 | Amgen Inc | Triazin-kinase-hemmer |
| MXPA02007957A (es) | 2000-02-17 | 2002-11-29 | Amgen Inc | Inhibidores de cinasas. |
| AU2001250783A1 (en) | 2000-02-29 | 2001-09-12 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| HUP0402352A2 (hu) | 2001-06-19 | 2005-02-28 | Bristol-Myers Squibb Co. | Foszfodiészteráz (PDE) 7 inhibitorként alkalmazható pirimidinszármazékok és ezeket tartalmazó gyógyszerkészítmények |
| WO2003030909A1 (en) | 2001-09-25 | 2003-04-17 | Bayer Pharmaceuticals Corporation | 2- and 4-aminopyrimidines n-substtituded by a bicyclic ring for use as kinase inhibitors in the treatment of cancer |
| SG10201510696RA (en) | 2008-06-27 | 2016-01-28 | Celgene Avilomics Res Inc | Heteroaryl compounds and uses thereof |
| CA2771190C (en) | 2009-08-17 | 2020-01-21 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| WO2011153553A2 (en) | 2010-06-04 | 2011-12-08 | The Regents Of The University Of California | Methods and compositions for kinase inhibition |
| CA2806341C (en) | 2010-07-29 | 2020-03-24 | Rigel Pharmaceuticals, Inc. | Ampk-activating heterocyclic compounds and methods for using the same |
| EP2696683A4 (en) | 2011-04-12 | 2014-08-13 | Alzheimer S Inst Of America Inc | COMPOSITIONS AND THERAPEUTIC APPLICATIONS OF IKK-MEDIATED KINASE EPSILON AND TANK BINDING KINASE-1 HEMMER |
| TWI663166B (zh) | 2013-04-24 | 2019-06-21 | 健生藥品公司 | 新化合物 |
| WO2015030847A1 (en) | 2013-08-30 | 2015-03-05 | Ptc Therapeutics, Inc. | Substituted pyrimidine bmi-1 inhibitors |
| TWI627173B (zh) | 2013-09-26 | 2018-06-21 | 比利時商健生藥品公司 | 作為ＮＩＫ抑制劑的新穎３－（１Ｈ－吡唑－４－基）－１Ｈ－吡咯并［２，３－ｃ］吡啶衍生物 |
| TWI704146B (zh) | 2013-09-26 | 2020-09-11 | 比利時商健生藥品公司 | 用作ＮＩＫ抑制劑之新的1-(４-嘧啶基)-１Ｈ-吡唑並[３,２-ｃ]吡啶衍生物 |
| LT3126352T (lt) | 2014-04-04 | 2019-01-10 | Syros Pharmaceuticals, Inc. | Nuo ciklino priklausomos kinazės 7 (cdk7) inhibitoriai |
| CN106536478A (zh) | 2014-05-22 | 2017-03-22 | 悉尼大学 | ω‑3类似物 |
| WO2016022645A1 (en) | 2014-08-06 | 2016-02-11 | Merck Sharp & Dohme Corp. | Heterocyclic cgrp receptor antagonists |
| JP6499282B2 (ja) * | 2014-09-26 | 2019-04-10 | ギリアード サイエンシーズ， インコーポレイテッド | Ｔａｎｋ結合キナーゼ阻害剤化合物として有用なアミノトリアジン誘導体 |
| CN106928216A (zh) | 2015-12-31 | 2017-07-07 | 中国科学院上海药物研究所 | 具有erk激酶抑制活性的化合物、其制备方法和用途 |
| WO2017125530A1 (en) | 2016-01-22 | 2017-07-27 | Janssen Pharmaceutica Nv | New substituted cyanoindoline derivatives as nik inhibitors |
| US11001569B2 (en) | 2016-01-22 | 2021-05-11 | Janssen Pharmaceutica Nv | 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors |
| BR112018068703B1 (pt) | 2016-03-16 | 2024-02-06 | Kura Oncology, Inc. | Inibidores substituídos de menin-mll e métodos de uso |
| ES2837157T3 (es) | 2016-06-30 | 2021-06-29 | Janssen Pharmaceutica Nv | Derivados de cianoindolina como inhibidores de NIK |
| CN109641882B (zh) | 2016-06-30 | 2022-10-28 | 杨森制药有限公司 | 作为nik抑制剂的杂芳族衍生物 |
-
2017
- 2017-06-29 CN CN201780053583.6A patent/CN109641882B/zh active Active
- 2017-06-29 ES ES17739902T patent/ES2805976T3/es active Active
- 2017-06-29 JP JP2018562331A patent/JP6936815B2/ja active Active
- 2017-06-29 KR KR1020197002588A patent/KR102517352B1/ko active Active
- 2017-06-29 CA CA3027416A patent/CA3027416A1/en active Pending
- 2017-06-29 WO PCT/EP2017/066120 patent/WO2018002217A1/en not_active Ceased
- 2017-06-29 AU AU2017289315A patent/AU2017289315B2/en not_active Ceased
- 2017-06-29 EP EP17739902.9A patent/EP3478675B1/en active Active
- 2017-06-29 US US16/309,059 patent/US11136311B2/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002079197A1 (en) * | 2001-03-29 | 2002-10-10 | Vertex Pharmaceuticals Incorporated | Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases |
| WO2009158011A1 (en) * | 2008-06-26 | 2009-12-30 | Amgen Inc. | Alkynyl alcohols as kinase inhibitors |
| WO2010042337A1 (en) * | 2008-10-07 | 2010-04-15 | Merck Sharp & Dohme Corp. | Novel 6-azaindole aminopyrimidine derivatives having nik inhibitory activity |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3027416A1 (en) | 2018-01-04 |
| JP6936815B2 (ja) | 2021-09-22 |
| EP3478675B1 (en) | 2020-04-22 |
| AU2017289315A1 (en) | 2019-01-24 |
| WO2018002217A1 (en) | 2018-01-04 |
| CN109641882A (zh) | 2019-04-16 |
| ES2805976T3 (es) | 2021-02-16 |
| KR102517352B1 (ko) | 2023-03-31 |
| US11136311B2 (en) | 2021-10-05 |
| CN109641882B (zh) | 2022-10-28 |
| KR20190025644A (ko) | 2019-03-11 |
| EP3478675A1 (en) | 2019-05-08 |
| JP2019521097A (ja) | 2019-07-25 |
| US20190359598A1 (en) | 2019-11-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017289315B2 (en) | Heteroaromatic derivatives as NIK inhibitors | |
| JP7675777B2 (ja) | 免疫調節剤としての複素環式化合物 | |
| AU2017286380B2 (en) | Azabenzimidazole derivatives as PI3K beta inhibitors | |
| AU2017209935B2 (en) | New substituted cyanoindoline derivatives as NIK inhibitors | |
| EP2943485B1 (en) | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors | |
| AU2017208555B2 (en) | New 6-membered heteroaromatic substituted cyanoindoline derivatives as NIK inhibitors | |
| AU2017289317B2 (en) | Cyanoindoline derivatives as NIK inhibitors | |
| CN104520290A (zh) | 酰氨基螺环酰胺和磺酰胺衍生物 | |
| AU2014259477A1 (en) | 3-(2-aminopyrimidin-4-yl)-5-(3-hydroxypropynyl)-1H-pyrrolo[2,3-c]pyridine derivatives as NIK inhibitors for the treatment of cancer | |
| AU2018297592B2 (en) | New substituted azaindoline derivatives as NIK inhibitors | |
| RU2780577C2 (ru) | Новые замещенные производные азаиндолина в качестве ингибиторов nik | |
| HK40097413B (en) | Heterocyclic compounds as immunomodulators | |
| HK40097413A (en) | Heterocyclic compounds as immunomodulators | |
| HK1261385B (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| HK1261385A1 (en) | New substituted cyanoindoline derivatives as nik inhibitors | |
| HK1216316B (en) | Bicyclic aromatic carboxamide compounds useful as pim kinase inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |